Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25087195 | 1.00 | TSHR (0.33) | TSHRAPLNRCA1CA2CA7 | |
| SCHEMBL24034198 | 1.00 | TSHR (0.33) | TSHRAPLNRCA1CA2CA7 | |
| SCHEMBL26316235 | 0.85 | APLNR (0.35) | APLNRCA1CA2CA7NOS1 | |
| SCHEMBL26316257 | 0.85 | APLNR (0.35) | APLNRCA1CA2CA7NOS1 | |
| SCHEMBL2466487 | 0.79 | TSHR (0.36) | TSHR | |
| SCHEMBL2462875 | 0.78 | TSHR (0.33) | TSHR | |
| SCHEMBL25086852 | 0.77 | ALDH1A1 (0.39) | TSHR | |
| SCHEMBL25087196 | 0.77 | ALDH1A1 (0.39) | TSHR | |
| SCHEMBL30068345 | 0.76 | CA1 (0.35) | APLNRCA1CA2CA7NOS1 | |
| SCHEMBL2463280 | 0.76 | TSHR (0.39) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4149941-B1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | ALGEN BIOTECHNOLOGIES INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12264152-B2 | Certain chemical compositions and methods of use thereof | ALGEN BIOTECHNOLOGIES, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20230295135-A1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | ALGEN BIOTECHNOLOGIES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295135-A1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | ALGEN BIOTECHNOLOGIES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295135-A1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | ALGEN BIOTECHNOLOGIES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11591322-B2 | Certain chemical compositions and methods of use thereof | ALGEN BIOTECHNOLOGIES, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11591322-B2 | Certain chemical compositions and methods of use thereof | ALGEN BIOTECHNOLOGIES, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220289725-A1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | ALGEN BIOTECHNOLOGIES, INC. | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289725-A1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | CDK9, CDK19, CDK6 | TSHR 4152/4885APLNR 3607/4885CA1 1644/4885 |
| US-11591322-B2 | Certain chemical compositions and methods of use thereof | CDK9, CDK19, CDK6 | TSHR 4152/4885APLNR 3607/4885CA1 1644/4885 |
| US-20230295135-A1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | CDK9, CDK19, CDK6 | TSHR 4152/4885APLNR 3607/4885CA1 1644/4885 |
| US-12264152-B2 | Certain chemical compositions and methods of use thereof | CDK9, CDK19, CDK6 | TSHR 4152/4885APLNR 3607/4885CA1 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.